Brokers Change Their Target Price On ImmunoCellular Therapeutics, Ltd. (IMUC)

Marco Green
September 14, 2017

ImmunoCellular Therapeutics Ltd is in oversold territory based on Relative Strength Index reading (16). The RSI oscillates between zero and 100. The other 0, though not evenly; between analysts who think you should buy ImmunoCellular Therapeutics, Ltd. versus those who think you should sell it.

ImmunoCellular Therapeutics, Ltd. (IMUC) lies in the middle of a very wide and falling trend in the short term and pointed towards extra losses. Wall Street is only getting more bullish on the stock, with 2 of analysts who cover HCI having a buy-equivalent rating. It represents a security's price that, if achieved, results in a trader recognizing the best possible outcome for his investment. It's now trading about -39.58% below its 52-week high. They now have a United States dollars 1.25 price target on the stock. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target.

05/13/2015 - ImmunoCellular Therapeutics, Ltd. was downgraded to "hold" by analysts at Zacks. Accern also gave press coverage about the company an impact score of 44.5051157377947 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. These ratios are important while doing valuation of the company or the shares of the company. Consensus earnings estimates are far from ideal, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. ImmunoCellular Therapeutics, Ltd. has 0 buy ratings, 1 holds and 0 sells even after the stock tumbled -94.97% from its high of $5.37 to a $4.39 million market value through last close.

P/E of the company is not reported.

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise.

Now the shares of ImmunoCellular Therapeutics, Ltd. (IMUC) has the trading volume of 3.1 Million shares with the average trading volume of 848680 shares. The company reported revenue of $0 in the same period previous year. Meanwhile, a price down versus the short-term MA will be a fresh sales call. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range. The share price has moved backward from its 20 days moving average, trading at a distance of -20.45% and stays -28.13% away from its 50 days moving average.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER